4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) posted its earnings results on Thursday. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.03), FiscalAI reports. The business had revenue of $4.14 million for the quarter, compared to the consensus estimate of $4.13 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.
4D Molecular Therapeutics Stock Performance
Shares of FDMT stock traded down $0.88 on Thursday, reaching $12.11. The company had a trading volume of 897,223 shares, compared to its average volume of 1,004,945. 4D Molecular Therapeutics has a one year low of $6.96 and a one year high of $16.93. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. The business’s 50-day moving average is $13.25 and its 200 day moving average is $11.03.
Insider Buying and Selling at 4D Molecular Therapeutics
In other news, insider David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $12.92, for a total transaction of $753,662.36. Following the sale, the insider directly owned 709,153 shares of the company’s stock, valued at approximately $9,162,256.76. This trade represents a 7.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 122,155 shares of company stock worth $1,635,925. Company insiders own 7.90% of the company’s stock.
Wall Street Analysts Forecast Growth
FDMT has been the topic of a number of research reports. Cantor Fitzgerald upgraded 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target on the stock in a report on Monday, September 14th. The Goldman Sachs Group reiterated a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Bank of America boosted their price target on 4D Molecular Therapeutics from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Tuesday, September 29th. Citigroup reissued a “buy” rating on shares of 4D Molecular Therapeutics in a report on Thursday, October 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, October 22nd. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $30.22.
Check Out Our Latest Research Report on FDMT
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc. is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company’s proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.
Read More
- Five stocks we like better than 4D Molecular Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
